Endo Pharmaceuticals (ENDP) and its majority-owned subsidiary Indevus Pharmaceuticals, Inc. (IDEV) said that the U.S. Food and Drug Administration has accepted for review the complete response submission to the new drug application for NEBIDO intramuscular injection, an investigational testosterone preparation for the treatment of male hypogonadism.
FDA is targeting September 2, 2009 as the action date for a decision on this application.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.